Clinical trials: Arteriosus
Patent Ductus Arteriosus
PDA Post NICU Discharge
The purpose of this study is to track post-discharge outcomes on prematurely born infants who are discharged from the NICU with a patent ductus arteriosus (PDA).
- Trial name
- PDA (NCT02750228)
- Where
- 16 sites in United States
- Volunteers
- 208 people
- Sponsor
- Pediatrix
Coronary Artery Disease, Acute Myocardial Infarction
Heart Cycle Prestudy
In this Prestudy which will be followed by the multicentral GEx- main-trial, the feasibility of a new cardiac rehabilitation device (GEx system) is proved with coronary heart disease patients who participate in cardiac…
- Trial name
- PreGEx (NCT01627457)
- Testing
- Guided Exercise (GEx) system
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- RWTH Aachen University
PDA
NIRS in PDA VLBW Infants
Aim of study: To conduct an observational study to collect cerebral and renal perfusion data through NIRS before and after treatment of PDA by medication or by PDA ligation.
- Trial name
- NCT02396004
- Testing
- Near Infrared Red Spectroscopy (NIRS)
- Where
- Singapore
- Volunteers
- 30 people
- Sponsor
- Singapore General Hospital
Patent Ductus Arteriosus
Paracetamol Versus Ibuprofen for PDA Closure
Comparison between the safety and efficacy of oral paracetamol and oral ibuprofen in treatment of Patent Ductus Arteriosus (PDA) in premature infants
- Trial name
- NCT03265782
- Testing
- ibuprofen, paracetamol
- Volunteers
- 30 people
- Sponsor
- Ain Shams University
Patent Ductus Arterioses
Impact of Transcatheter Patent Ductus Arteriosus Closure on Left Atrial and Ventricular Remodeling in Adults and Adolescents.
During the fetal life, small portion of the RV output passes to the lung through the pulmonary artery, while the greater portion is shunted to the descending aorta through the fetal ductus arteriosus (1) which is a connection…
- Trial name
- NCT07568002
- Testing
- Transcatheter Patent Ductus Arteriosus Closure
- Volunteers
- 40 people
- Sponsor
- Emil Magdy Badry
Complex Congenital Heart Defect, Dysfunctional RVOT Conduit
COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction
This study will demonstrate the safety and effectiveness of the Edwards Lifesciences SAPIEN 3/SAPIEN 3 Ultra RESILIA Transcatheter Heart Valve (THV) Systems in subjects with a dysfunctional right ventricular outflow tract (RVOT)…
- Conditions
- Complex Congenital Heart Defect, Dysfunctional RVOT Conduit, Pulmonary Valve Insufficiency, Pulmonary Valve Degeneration
- Trial name
- NCT02744677
- Testing
- SAPIEN 3/SAPIEN 3 Ultra RESILIA THV, SAPIEN 3 THV, SAPIEN 3 Ultra RESILIA THV
- Where
- 27 sites in United States
- Volunteers
- 108 people
- Sponsor
- Edwards Lifesciences
Hemodynamically Significant PDA
Comparative Analysis of Isolated Venous, Isolated Arterial, and Standard Access for Transcatheter Closure of Patent Ductus Arteriosus (PDA)
We enrolled all patients with a hemodynamically significant PDA demonstrated by patient clinical condition, and by PDA size \& left chamber dilatation on echocardiography attending at Cardiology Department to we compare the use…
- Trial name
- NCT06763978
- Testing
- Transcatheter PDA closure
- Where
- Egypt
- Volunteers
- 357 people
- Sponsor
- Egyptian Biomedical Research Network
Prematurity, Respiratory Distress Syndrome
Curosurf and Survanta Treatment(CAST)of RDS in Very Premature Infants
Approval of surfactant by the FDA in 1989 for the treatment of Respiratory Distress Syndrome (RDS) in premature infants greatly improved survival rates.
- Conditions
- Prematurity, Respiratory Distress Syndrome, Patent Ductus Arteriosus
- Trial name
- CAST (NCT00767039)
- Testing
- Survanta (beractant), Curosurf (poractant)
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Alan Fujii
Patent Ductus Arteriosus After Premature Birth
Hemodynamically Important Patent Ductus Arteriosus in Newborns Under 32 Weeks
To define the characteristics of hemodynamically significant PDA by echocardiography, to investigate the systemic effects of the ductus with cerebral and renal Doppler flow studies, and to determine the oxygen consumption in the…
- Trial name
- NCT05686343
- Testing
- Echocardiography, Doppler ultrasonography, Near-infrared spectroscopy
- Where
- Turkey (Türkiye)
- Volunteers
- 70 people
- Sponsor
- Ankara University
Patent Ductus Arteriosus, Prematurity; Extreme
A NEW SCORING SYSTEM FOR PREDICTION OF PDA
Patent ductus arteriosus (PDA) is an important morbidity of that the diagnosis and treatment is controversy in premature infants.
- Trial name
- SIMPLE (NCT04270240)
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people
- Sponsor
- Kanuni Sultan Suleyman Training and Research Hospital
Patent Ductus Arteriosus, Preterm Infant
Early Prediction of Spontaneous Patent Ductus Arteriosus (PDA) Closure and PDA-Associated Outcomes
Patent ductus arteriosus (PDA), very common in preterm infants, is the delayed closure of a fetal blood vessel that limits blood flow through the lungs.
- Conditions
- Patent Ductus Arteriosus, Preterm Infant, Bronchopulmonary Dysplasia, Neurodevelopmental Abnormality
- Trial name
- NCT03782610
- Where
- 4 sites in United States
- Volunteers
- 526 people
- Sponsor
- Nationwide Children's Hospital
Patent Ductus Arteriosus, Duct-dependent Cyanotic Congenital Heart Disease
Feasibility, Efficacy and Safety of IBS ® for Implantaiton in the PDA in Duct-dependent Cyanotic CHD
This is a pilot study on feasibility, efficacy and safety of IBS ® for implantation in the PDA in duct-dependent cyanotic CHD, and its objective is to investigate the feasibility, safety and efficacy of iron resorbable stent…
- Trial name
- NCT04291222
- Testing
- Iron biocorrodable coronary scaffold system
- Where
- Malaysia
- Volunteers
- 10 people
- Sponsor
- Lifetech Scientific (Shenzhen) Co., Ltd.
Patent Ductus Arteriosus
HeartR™ PDA Occluder Post-Market Follow-Up Study
The HeartR™ PDA Occluder Post-Market Clinical Follow-up (PMCF) Study is a multi-center, retrospective, single-arm study sponsored by Lifetech Scientific (Shenzhen) Co., Ltd., aiming to evaluate the long-term safety and…
- Trial name
- NCT07646704
- Testing
- HeartR™ PDA Occluder
- Where
- Indonesia
- Volunteers
- 140 people
- Sponsor
- Lifetech Scientific (Shenzhen) Co., Ltd.
Patent Ductus Arteriosus
Oral Paracetamol Versus Oral Ibuprofen in Management of Patent Ductus Arteriosus in Preterm Infants: A Randomised Controlled Trial
The purpose of this study is to determine whether oral paracetamol or ibuprofen has a better or same efficacy and tolerance in closure of patent ductus arteriosus in preterm infants.
- Trial name
- NCT01536158
- Testing
- Oral paracetamol, Oral ibuprofen
- Where
- Turkey (Türkiye)
- Volunteers
- 80 people
- Sponsor
- Zekai Tahir Burak Women's Health Research and Education Hospital
Patent Ductus Arteriosus, Preterm
Precision Dosing of Oral Ibuprofen for PDA, A Pilot RCT
Newborns born early are at risk for a serious health problem called patent ductus arteriosus (PDA). PDA is a passageway between heart and lung that can cause life-threatening complications such as bleeding in the brain or even…
- Trial name
- MIPD-PDA (NCT07143201)
- Testing
- Standard Dose - Ibuprofen oral suspension, Precision Dose - Ibuprofen oral suspension
- Where
- Canada
- Volunteers
- 26 people
- Sponsor
- Hamilton Health Sciences Corporation
Patent Ductus Arteriosus
An Escalating Dose Indomethacin for the Treatment of Persistent Patent Ductus Arteriosus (PDA) In Preterm Infants
A large patent ductus arteriosus (PDA) is associated with congestive heart failure, pulmonary hemorrhage, chronic lung disease (CLD), necrotizing enterocolitis (NEC) and intraventricular bleeding.
- Trial name
- NCT00750581
- Testing
- Indomethacin
- Where
- Canada
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- University of Calgary
Patent Ductus Arteriosus in Preterm Infants
Radiological Markers for PDA Management in Preterm Infants
The aim of this Randomized controlled trial is to determine whether Echo with Organ Doppler-guided management strategy for hemodynamically significant patent ductus arteriosus (hsPDA) improves the short-term outcomes compared…
- Trial name
- NCT07812064
- Testing
- Organ doppler, Echocardiography
- Volunteers
- 88 people
- Sponsor
- Assiut University
Left Ventricular Hypertrophy
Postnatal Steroids Effects on Cardiac Function in Extremely Preterm
Hypothesis/Study question In infants born at less than 29 weeks of estimated gestational age, what are the effects of dexamethasone use on cardiac structure/performance and lung water content? Study objectives To measure effects…
- Trial name
- SPEC (NCT04644094)
- Testing
- Echocardiography (ECHO) and lung ultrasound (LUS) studies before and after Dexamethasone administration
- Where
- Canada
- Volunteers
- 21 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Patent Ductus Arteriosus After Premature Birth
Co-administration of Acetaminophen With Ibuprofen to Improve Duct-Related Outcomes in Extremely Premature Infants
Patent ductus arteriosus (PDA), the most common cardiovascular complication of prematurity, is associated with higher mortality and morbidities in extremely low gestational age neonates (ELGANs, < 27+0 weeks).
- Trial name
- NCT05340582
- Testing
- Acetaminophen Injection, Ibuprofen 20 mg/mL oral suspension or Ibuprofen lysine 10 mg/mL injection solution (Neoprofen), Sodium chloride 0.9% injection
- Where
- 9 sites in Australia, Canada and 2 more
- Volunteers
- 310 people
- Sponsor
- Mount Sinai Hospital, Canada
Prematurity of Fetus, Patent Ductus Arteriosus
Influence of Treatment for Patent Ductus Arteriosus on Cerebral Oxygenation in Preterm Infants
The purpose of this study is to examine the influence medical or surgical treatment for patent ductus arteriosus in preterm infants on cerebral and renal tissue oxygenation and on cardiac output.
- Trial name
- NCT01428180
- Testing
- Indomethacin, Surgical Ligation, Ibuprofen
- Where
- Germany
- Volunteers
- 35 people
- Sponsor
- University of Ulm